{"id":49506,"date":"2022-10-11T20:01:46","date_gmt":"2022-10-11T18:01:46","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/"},"modified":"2022-10-11T20:01:46","modified_gmt":"2022-10-11T18:01:46","slug":"medicaid-plans-growth-slows-in-core-expenses-in-2021","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/","title":{"rendered":"Medicaid Plans Growth Slows in Core Expenses in 2021"},"content":{"rendered":"
\n

PHILADELPHIA–(BUSINESS WIRE)–\u201cCore\u201d per member administrative expenses in Medicaid-focused plans grew by 2.6% in 2021, decelerating from 2020\u2019s increase of 5.8%. Core expenses exclude the plans\u2019 Sales and Marketing expense clusters.\n<\/p>\n

<\/a><\/p>\n

\nAll clusters of expenses posted slower growth compared to last year with the largest deceleration in Account and Membership Administration. These comparisons are of continuously reporting plans and eliminate the effects of product mix changes between comparison years.\n<\/p>\n

\nCore compensation and outsourcing increased in 2021, while Medicaid staffing ratios and non-labor expenses were lower.\n<\/p>\n

\nThese results are excerpted from the Medicaid Plans edition of the 2022 Sherlock Benchmarks<\/i>.\n<\/p>\n

\nFourteen plans were surveyed for this analysis. On average, 59% of members and 46% of revenues were in Medicaid HMO and CHIP. The Benchmarks<\/i> reflect the results of 8.1 million Medicaid HMO members. Including plans from other Sherlock universes but mentioned in the study, this participation equates to an estimated 15% of Medicaid HMO beneficiaries. The results are published in Plan Management Navigator<\/i> and are posted here<\/a>. This Navigator<\/i> excerpts from the 2022 Medicaid edition of the Sherlock Benchmarks<\/i>.\n<\/p>\n

\nWe will discuss the results via free web conference on Thursday, October 13, from 2:00 PM to 2:45 PM Eastern Daylight Time. Douglas Sherlock will offer a presentation, followed by questions and answers. To participate in the web conference, please register at sherlockco.com\/webinar<\/a>. Once registered, dial-in information and a link to connect will be provided in a confirmation email.\n<\/p>\n

\nThis operating environment has been challenging for health plans. The Sherlock Benchmarks<\/i> can assist in adapting to it by helping to optimize expenses. Planning, budgeting and cost benefit analyses are credibly informed by the Sherlock Benchmarks<\/i>.\n<\/p>\n

\nSherlock Benchmarks<\/i> reflect 963 health plan years spanning 25 years. They are the \u201cgold standard\u201d of health plan cost benchmarks and are used to measure and manage administrative activities in health plans serving over 210 million members.\n<\/p>\n

\nBesides the Medicaid-focused universe, other universes include Blue Cross Blue Shield Plans, Independent \/ Provider \u2013 Sponsored plans, Medicare plans, and Larger Plans. Collectively, the 34 participating plans serve 63 million people.\n<\/p>\n

\nSherlock Company (www.sherlockco.com<\/a>), based in Gwynedd Valley, Pennsylvania, provides informed solutions for health plan financial management. Since its founding in 1987, Sherlock Company has been known for its impartiality and technical competence in service to its clients.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nDouglas B. Sherlock, CFA
\n
215-628-2289
\n
sherlock@sherlockco.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

PHILADELPHIA–(BUSINESS WIRE)–\u201cCore\u201d per member administrative expenses in Medicaid-focused plans grew by 2.6% in 2021, decelerating from 2020\u2019s increase of 5.8%. Core expenses exclude the plans\u2019 Sales and Marketing expense clusters. All clusters of expenses posted slower growth compared to last year with the largest deceleration in Account and Membership Administration. These comparisons are of continuously … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":["entry","post","publish","author-business","post-49506","format-standard","category-industry"],"yoast_head":"\nMedicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Medicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"PHILADELPHIA–(BUSINESS WIRE)–\u201cCore\u201d per member administrative expenses in Medicaid-focused plans grew by 2.6% in 2021, decelerating from 2020\u2019s increase of 5.8%. Core expenses exclude the plans\u2019 Sales and Marketing expense clusters. All clusters of expenses posted slower growth compared to last year with the largest deceleration in Account and Membership Administration. These comparisons are of continuously ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-10-11T18:01:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Medicaid Plans Growth Slows in Core Expenses in 2021\",\"datePublished\":\"2022-10-11T18:01:46+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/\"},\"wordCount\":382,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011006074\\\/en\\\/1598702\\\/21\\\/Sherlock_Company_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/\",\"name\":\"Medicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011006074\\\/en\\\/1598702\\\/21\\\/Sherlock_Company_Logo.jpg\",\"datePublished\":\"2022-10-11T18:01:46+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011006074\\\/en\\\/1598702\\\/21\\\/Sherlock_Company_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221011006074\\\/en\\\/1598702\\\/21\\\/Sherlock_Company_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/medicaid-plans-growth-slows-in-core-expenses-in-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Medicaid Plans Growth Slows in Core Expenses in 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Medicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/","og_locale":"en_US","og_type":"article","og_title":"Medicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend","og_description":"PHILADELPHIA–(BUSINESS WIRE)–\u201cCore\u201d per member administrative expenses in Medicaid-focused plans grew by 2.6% in 2021, decelerating from 2020\u2019s increase of 5.8%. Core expenses exclude the plans\u2019 Sales and Marketing expense clusters. All clusters of expenses posted slower growth compared to last year with the largest deceleration in Account and Membership Administration. These comparisons are of continuously ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/","og_site_name":"Pharma Trend","article_published_time":"2022-10-11T18:01:46+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Medicaid Plans Growth Slows in Core Expenses in 2021","datePublished":"2022-10-11T18:01:46+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/"},"wordCount":382,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/","url":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/","name":"Medicaid Plans Growth Slows in Core Expenses in 2021 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg","datePublished":"2022-10-11T18:01:46+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221011006074\/en\/1598702\/21\/Sherlock_Company_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/medicaid-plans-growth-slows-in-core-expenses-in-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Medicaid Plans Growth Slows in Core Expenses in 2021"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49506","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=49506"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/49506\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=49506"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=49506"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=49506"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}